Figure 3 | Scientific Reports

Figure 3

From: Genome-wide CRISPR/Cas9 screening in human iPS derived cardiomyocytes uncovers novel mediators of doxorubicin cardiotoxicity

Figure 3

Genome-scale CRISPR/Cas9 screen in iPS derived cardiomyocytes for mediators of doxorubicin-toxicity. (a) Dose response curve for doxorubicin-toxicity in iPS derived cardiomyocytes (circulating concentration range highlighted in red, n = 8 per condition). (b) Distribution of fold change scores in doxorubicin (dox) versus control (ctrl) treated cardiomyocytes. SLCO1A2 and SLCO1B3 indicated by blue and red arrows, respectively. (c), and (d) Enrichment scores for individual sgRNAs targeting SLCO1A2 and SLCO1B3. (e) Western-blot for protein expression of SLCO1A2 and SLCO1B3 in human iPS derived cardiomyocytes. Full-length blots are included in Supplementary Figure 10a–b. (f) Western-blot for protein expression of SLCO1A2 and SLCO1B3 in human heart tissue. Full-length blots are included in Supplementary Figure 10c–d.

Back to article page